This site is intended for healthcare professionals
News

First patient randomised in the phase III DISSOLVE clinical programme of SE L212 for chronic refractory gout.- SOBI + Selecta Biosciences

Read time: 1 mins
Last updated:24th Sep 2020
Published:24th Sep 2020
Condition: Gout
Type: drug
Register free for full access to medthority.com